Fennec, Tampa General launch real-world PEDMARK oncology study

Fennec Pharmaceuticals ( (TSE:FRX) ) just unveiled an announcement.

On March 4, 2026, Fennec Pharmaceuticals announced that Tampa General Hospital Cancer Institute is launching a clinical research collaboration to evaluate the real-world utility of PEDMARK, its sodium thiosulfate injection, in reducing cisplatin-related hearing loss in adolescent, young adult and adult cancer patients with non-metastatic solid tumors. The initiative, which will incorporate real-world clinical data and audiology monitoring beyond controlled trial settings, is expected to deepen understanding of PEDMARK’s role across broader patient populations and tumor types, potentially strengthening Fennec’s position in the oncology supportive care market and informing future research and quality-of-care efforts around ototoxicity.

The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.

Spark’s Take on TSE:FRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.

The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.

To see Spark’s full report on TSE:FRX stock, click here.

More about Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy through the commercialization of its sodium thiosulfate injection product PEDMARK. The drug, approved by the FDA in 2022 and by European regulators in 2023 under the brand name PEDMARQSI, benefits from orphan drug and market exclusivity protections and is being rolled out in partnership with Norgine across Europe, the U.K., Australia and New Zealand.

Fennec’s flagship therapy PEDMARK is the first and only FDA-approved treatment to reduce the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. With established Phase 3 efficacy data and growing international commercialization, the company is positioning itself as a leader in otoprotection within oncology supportive care markets.

Average Trading Volume: 827

Technical Sentiment Signal: Buy

Current Market Cap: C$373.8M

Learn more about FRX stock on TipRanks’ Stock Analysis page.